Others titles

  • Psychiatric Hospital Compare Data by Facility
  • Inpatient Hospital Quality Measures
  • CMS Quality Measures Data
  • IPQRF Program Quality Measures
  • Inpatient Psychiatric Hospital Facility Quality Measures
  • Inpatient Psychiatric Hospital Facility Quality Reporting Program

Keywords

  • Quality Reporting Programs
  • Quality Reporting Payments
  • Quality of Care Information
  • Eligible Psychiatric Hospitals
  • Psychiatric Hospital
  • Psychiatric Services
  • CMS Hospital Compare
  • Psychiatric Hospital Facilities

Inpatient Psychiatric Hospital Facility Quality Measures by State

This dataset includes Psychiatric facilities that are eligible for the Inpatient Psychiatric Facility Quality Reporting (IPFQR) program are required to meet all program requirements, otherwise their Medicare payments may be reduced. It contains state-wise data for the hospitals in United States for several inpatient psychiatric facility quality measures.

Log in to download
Complexity

Get The Data

For getting access to data download links please read and accept the end-user license agreement.
Your Data License
  • Research
    Non-Commercial, Share-Alike, Attribution Free Forever
  • Commercial
    Commercial Use, Remix & Adapt, White Label Log in to download

John Snow Labs Standard End User License Agreement

Last updated:January 20, 2021

This Standard End User License Agreement (“EULA”) applies to customers of John Snow Labs Inc. (as defined below), using any product of John Snow Labs Inc. on John Snow Labs Marketplace as defined below (hereinafter referred to “you”) and John Snow Labs Inc., a Delaware corporation (“John Snow Labs”, “we” or “us”).

By downloading, installing, and/or using (as applicable) any Product of John Snow Labs (as defined below), you automatically agree to be bound by, and use our Products in compliance with, this EULA. This EULA, together with additional terms and conditions and/or policies referenced herein or located on https://www.johnsnowlabs.com and/or conveyed to you by John Snow Labs, is a legally binding contract between you and John Snow Labs.

PLEASE READ THIS EULA CAREFULLY BEFORE PURCHASING, INSTALLING OR USING OUR PRODUCTS MADE AVAILABLE ON JOHN SNOW LABS MARKETPLACE.

We may make changes to this EULA from time to time. When we do so, we will revise the “last updated” date given above. The then-current version of this EULA will supersede all earlier versions. You agree that your continued use of our Products after such changes have been published to our EULA will constitute your acceptance of such revised EULA.

Definitions

“John Snow Labs Data Library” means a data library located at https://www.johnsnowlabs.com;

“Products” means products and services of John Snow Labs that you download and use from listings in John Snow Labs Data Library;

Important Notice

By installing and using our Products, you acknowledge that the use of the Products can be subject to the restrictions and controls imposed by United States export regulations.

You represent and warrant that you do not intend to use the Products for any purpose prohibited by United States export regulations, including, without limitation, terrorism, cyber-attacks, cyber-crimes, money-laundering, industrial espionage, or nuclear, chemical or biological weapons proliferation. Further, you represent and warrant that you are not listed as a denied party on any list governing United States exports.

Eligibility

Our Products can be used by an individual, business or other legal entity, or both. If you are entering into this EULA, or using the Products, on behalf of a company or other legal entity, you represent that you have the authority to bind such entity to this EULA, in which case “you” shall refer to such entity.

In the event you have entered into a separate written agreement with John Snow Labs regarding the Products that contemplates terms that are inconsistent with this EULA, the written agreement shall control and this EULA will not apply to you to the extent inconsistent with such written agreement, or, if such written agreement is contemplated to be in lieu of this EULA, then this EULA shall not apply at all.

Your Access and Use

Subject to your compliance with this EULA, as well as any other applicable policies, John Snow Labs grants you non-exclusive, non-transferable, license to install, access to, modify, and use of, the Products worldwide (subject to applicable export laws) during the term of this EULA (as described below) solely for research, private study and personal use of Products.

This license is personal to you, and you may not resell our Products, permit other users access to our Products through your account. Your right to use our Products is limited by all terms and conditions set forth in this EULA.

Except for your pre-existing rights and this license granted to you, we and our licensors retain all rights, titles and interests in and to our Products, all related intellectual property rights, including trademarks (whether registered or pending), domain and business names. Our Products are protected by applicable intellectual property laws, including United States copyright law and international treaties.

Except for the foregoing license, you have no other rights in the Products and you may not modify, edit, copy, reproduce, create derivative works of, reverse engineer, alter, enhance or in any way exploit the Products in any manner. If you breach any of this EULA, the above license will terminate automatically.

You will be deemed to have taken any action that you permit, assist or facilitate any person or entity to take related to this EULA, your content or use of the Products. You are responsible for end users’ use of your content and the Products. You will ensure that all end users comply with your obligations under this EULA and that the terms of your agreement with each end user are consistent with this EULA. If you become aware of any violation of your obligations under this EULA caused by an end user, you will immediately suspend access to your content and the Products by such end user. We do not provide any support or services to end users unless we have a separate agreement with you or an end user obligating us to provide such support or services.

Restrictions

You will access or use our Products solely via John Snow Labs Data Library.

Except as otherwise explicitly provided in this EULA or as may be expressly permitted by applicable law, you will not, and will not permit or authorize any third party to:

  1. reproduce, modify, translate, enhance, decompile, disassemble, reverse engineer or create derivative works of any of our Products or its technological features or measures;
  2. rent, lease, sell, resell, loan, distribute, or sublicense access to any of our Products;
  3. circumvent or disable any security or technological features or measures of our Products;
  4. use our intellectual property rights without our express prior written authorization;
  5. use our Products for more than one trial period, unless the trial period is extended by John Snow Labs’ prior written permit;
  6. use our Products with an intent to build a competitive product or service, or copy or substantially copy any ideas, features, functions, organization, structure, application program interface, graphics, or user interface of the Products;
  7. store, copy, modify, distribute, or resell any of the information; audio, visual, and audiovisual works, or other content made available on our Products (collectively, “Content”) or compile or collect any Content as part of a database or other work;
  8. use any automated tool (e.g., robots, spiders) to access or use our Products, or to store, copy, modify, distribute, or resell any Content;
  9. circumvent or disable any rights management, usage rules, or other security features of our Products;
  10. use our Products in a manner that overburdens, or that threatens the integrity, performance, or availability of, our Products; or
  11. remove, alter, or obscure any proprietary notices (including copyright and trademark notices) on any portion of our Products or any Content.

Fees and Taxes

Your use of the Products is subject to our fees. All fees are given on our website https://www.johnsnowlabs.com. Except as set forth in this EULA, the fees are non-refundable. We are entitled to revise our fees from time to time.

The fees exclude any federal, state or local taxes, VAT, GST, or similar taxes. You are responsible for identification and payment of all taxes as required by applicable law.

Term and Termination

This EULA will become effective as of the date of your order of Products and shall be in effect until terminated.

John Snow Labs may suspend or terminate your right to use our Products, if you or your end user’s use of the Products:

  1. is in breach of this EULA;
  2. poses a security risk to our Products;
  3. could adversely impact our systems, the Products or other customers;
  4. could subject us, our affiliates, or any third party to liability; or
  5. could be fraudulent.

We may also suspend or terminate your right to use our Products, if you fail to perform your payment obligations, or you have ceased to operate in the ordinary course, made an assignment for the benefit of creditors or similar disposition of your assets, or become the subject of any bankruptcy, reorganization, liquidation, dissolution or similar proceeding.

We may also suspend or terminate your right to use our Products without any reason upon a relevant 30 days’ written notice to you and will refund the unused fees pre-paid by you for access to the Products for the affected time period (if any). Where your access is suspended or terminated by the breach of this EULA or applicable laws, John Snow Labs will will not provide, or be liable for, any refund.

You will cease use of the Products during any period of suspension, or upon termination of this EULA.

All provisions which by their nature are intended to survive termination shall survive termination of this EULA.

Support

If applicable to your Product, John Snow Labs will provide you with the support services. If you use a trial access, support services are excluded. Under this EULA, our support services exclude any installation, training, maintenance services (including any error corrections, bug fixes, or new releases), technical assistance, consulting services, or other services of any kind. Such services are provided at John Snow Labs’ discretion.

From time to time John Snow Labs can perform updates to our software. If available, such updates may include bug fixes, new features and/or enhancements. You are solely responsible for deploying such updates at your own risk and liability.

Access to our Products

We do not provide you with the equipment to access our Products. You are responsible for all fees charged by third parties related to your access and use of our Products (e.g., charges by Internet service providers).

You are responsible for monitoring your use of the Products, including payment of all fees and/or taxes related to such access and use. You agree that John Snow Labs is permitted to request and you hereby consent to provide John Snow Labs information related to your use of the Products for auditing purposes.

You also certify that you are legally permitted to use the Products, and take full responsibility for the selection and use of the Products. This EULA is void where prohibited by law, and the right to use the Products is revoked in such jurisdictions. John Snow Labs makes no claim that the Products may be lawfully used outside of the United States. If you use the Products from outside of the United States, you do so at your own risk and you are responsible for compliance with the laws of jurisdiction.

Privacy Policy

We may collect, store and receive personal and other information about you through our Products. Our collection and use of this information is governed by our Privacy Policy available at https://www.JohnSnowLabs.com/privacy/ which may be amended from time to time.

Links and Third Party Content

Our Products may display, or contain links to, third party products, services, and websites. Any opinions, advice, statements, services, offers, or other information that constitutes part of the content expressed, authored, or made available by other users or other third parties, or which is accessible through or may be located using our Products (collectively, “Third Party Content”) are those of the respective authors or producers and not of us or our shareholders, directors, officers, employees, agents, or representatives.

We do not control Third Party Content and do not guarantee the accuracy, integrity or quality of such Third Party Content. We are not responsible for the performance of, we do not endorse, and we are not responsible or liable for, any Third Party Content or any information or materials advertised in any Third Party Content. By using our Products, you may be exposed to content that is offensive, indecent, or objectionable. We are not responsible or liable, directly or indirectly, for any damage or loss caused to you by your use of or reliance on any goods, services, or information available on or through any third party service or Third Party Content. It is your responsibility to evaluate the information, opinion, advice, or other content available on and through our Products.

Proprietary Rights

John Snow Labs will not obtain any rights under this EULA from you (or your licensors) to your content.

The Products, including software, is and remains the exclusive property of John Snow Labs and its licensors. Except for the access and use rights expressly set forth in this EULA, no license or other rights in or to the Products or John Snow Labs trademark(s) and other intellectual property rights therein, are granted to you, and all such licenses and rights are expressly reserved. You will not remove, alter, or obscure any proprietary notices (including copyright and trademark notices) on any portion of our Products or any Content.

Trademarks

“John Snow Labs,” the John Snow Labs logo, and any other product, business or service name or slogan, whether registered or pending, displayed on our Products are trademarks of John Snow Labs, Inc. or its suppliers or licensors, and may not be copied, imitated or used, in whole or in part, without the prior written permission of John Snow Labs or the applicable trademark holder. You may not use any metatags or any other “hidden text” utilizing “John Snow Labs” or any other name, trademark or product, business or service name of John Snow Labs without our prior written permission. In addition, the look and feel of our Products, including all page headers, custom graphics, button icons and scripts, is the service mark, trademark and/or trade dress of John Snow Labs and may not be copied, imitated or used, in whole or in part, without our prior written permission. All other trademarks, pending trademarks, registered trademarks, product names and company names or logos mentioned in our Products are the property of John Snow Labs Inc. and/or their respective owners. Reference to any products, services, processes or other information, by trade name, trademark, manufacturer, supplier, or otherwise does not constitute or imply endorsement, sponsorship, or recommendation thereof by us.

Disclaimer of Warranties

YOUR USE OF THE PRODUCTS IS AT YOUR SOLE RISK. THE PRODUCTS AND CONTENT EACH ARE PROVIDED ON AN “AS IS” AND “AS AVAILABLE” BASIS. WE AND OUR SUPPLIERS AND LICENSORS EXPRESSLY DISCLAIM ALL WARRANTIES OF ANY KIND, WHETHER EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, TITLE, AND NON-INFRINGEMENT. WE DO NOT GUARANTEE THE ACCURACY, COMPLETENESS, OR USEFULNESS OF THE PRODUCTS OR ANY CONTENT, AND YOU RELY ON THE PRODUCTS AND CONTENT AT YOUR OWN RISK. ANY MATERIAL THAT YOU ACCESS OR OBTAIN THROUGH OUR PRODUCTS IS DONE AT YOUR OWN DISCRETION AND RISK AND YOU WILL BE SOLELY RESPONSIBLE FOR ANY DAMAGE TO YOUR COMPUTER OR LOSS OF DATA THAT RESULTS FROM THE DOWNLOAD OF ANY MATERIAL THROUGH OUR PRODUCTS. NO ADVICE OR INFORMATION, WHETHER ORAL OR WRITTEN, OBTAINED BY YOU FROM US OR THROUGH OR FROM OUR PRODUCTS WILL CREATE ANY WARRANTY NOT EXPRESSLY STATED IN THIS EULA. SOME STATES MAY PROHIBIT A DISCLAIMER OF WARRANTIES AND YOU MAY HAVE OTHER RIGHTS THAT VARY FROM STATE TO STATE.

Limitation of Liability

WE AND OUR SUPPLIERS AND LICENSORS WILL NOT BE LIABLE FOR ANY DIRECT, INDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL, OR EXEMPLARY DAMAGES, INCLUDING BUT NOT LIMITED TO, DAMAGES FOR LOSS OF PROFITS, GOODWILL, USE, DATA, OR OTHER INTANGIBLE LOSSES (EVEN IF WE HAVE BEEN ADVISED OF THE POSSIBILITY OF THESE DAMAGES), RESULTING FROM YOUR USE OF OUR PRODUCTS AND CONTENT. UNDER NO CIRCUMSTANCES WILL THE TOTAL LIABILITY OF US AND OUR SUPPLIERS AND LICENSORS OF ALL KINDS ARISING OUT OF OR RELATED TO YOUR USE OF THE PRODUCTS AND CONTENT (INCLUDING BUT NOT LIMITED TO WARRANTY CLAIMS), REGARDLESS OF THE FORUM AND REGARDLESS OF WHETHER ANY ACTION OR CLAIM IS BASED ON CONTRACT, TORT, OR OTHERWISE, EXCEED THE AMOUNTS, IF ANY, THAT YOU HAVE PAID FOR YOUR USE OF THE PRODUCTS AND CONTENT. BECAUSE SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF LIABILITY FOR CONSEQUENTIAL OR INCIDENTAL DAMAGES, THE ABOVE LIMITATION MAY NOT APPLY TO YOU.

Indemnity

To the full extent permitted by applicable law, you shall defend, indemnify and hold harmless John Snow Labs, its affiliates and its licensors, and each of their respective employees, officers, directors, and representatives from and against any claims, damages, losses, liabilities, costs, and expenses (including reasonable attorney’s fees) arising out of or relating to any third party claim concerning: (a) your use of the Products; (b) breach of this EULA or violation of applicable law by you; (c) any content or the combination of such content with other software, content or processes, including any claim involving alleged infringement or misappropriation of third-party rights by such content or combination; or (d) breach of any obligation or duty you owe to a third party.

Legal Notices

Enforcement of this EULA will be governed by the laws of the State of Delaware, excluding its conflict and choice of law principles. The exclusive jurisdiction and venue for any claims arising out of or related to this EULA or your use of the Products will lie in the state and federal courts located in Sussex County, within the State of Delaware, and you irrevocably agree to submit to the jurisdiction of such courts. Our failure to enforce any right or provision in this EULA will not constitute a waiver of such right or provision unless acknowledged and agreed by us in writing. In the event that a court of competent jurisdiction finds any provision of this EULA to be illegal, invalid, or unenforceable, the remaining provisions will remain in full force and effect.

Notifications

We may use your contact information to notify you if we have any legitimate interest or if we need to notify you on any important information related to your use of Products. We will not send you newsletters unless you expressly consented to such notifications.

Contacting Us

If you have any questions or concerns about our Products or this EULA, you may contact us by email at support@JohnSnowLabs.com.

Description

The Inpatient Psychiatric Facility Quality Reporting (IPFQR) program is being developed as mandated by section 1886(s)(4) of the Social Security Act (SSA), as added and amended by Sections 3401(f) and 10322(a) of the Affordable Care Act (Pub.L. 111-148). The IPFQR program is a pay-for-reporting program intended to equip consumers with quality of care information to make more informed decisions about healthcare options. It is also intended to encourage hospitals and clinicians to improve the quality of inpatient care provided to beneficiaries by, first, ensuring that providers are aware of and reporting on best practices for their respective facilities and type of care. Because this is a pay-for-reporting program, facilities will be subject to payment reduction for non-participation. Eligible hospitals that do not participate in the IPFQR program in a fiscal year will receive a 2.0 percentage point reduction to their annual update to their standard federal rate for that year. The reduction is noncumulative across payment years.

The IPFQR program requires facilities to submit data for specific inpatient psychiatric clinical process measures. These quality measures will be announced no later than October 1, 2012. To meet the IPFQR program requirement, Inpatient Psychiatric Facilities (IPFs) will be required to submit all quality measures in the form, manner, and time as specified by the Secretary, to the Centers for Medicare & Medicaid Services (CMS), beginning with Fiscal Year (FY) 2014 payment determination year and subsequent fiscal years. Participating IPFs must comply with the program requirements, which will be set forth through rule-making, including public reporting of the measure rates.

About this Dataset

Data Info

Date Created

2014-01-28

Last Modified

2023-07-05

Version

2023-07-05

Update Frequency

Quarterly

Temporal Coverage

2014-2022

Spatial Coverage

United States

Source

John Snow Labs; Centers for Medicare & Medicaid Services;

Source License URL

Source License Requirements

N/A

Source Citation

N/A

Keywords

Quality Reporting Programs, Quality Reporting Payments, Quality of Care Information, Eligible Psychiatric Hospitals, Psychiatric Hospital, Psychiatric Services, CMS Hospital Compare, Psychiatric Hospital Facilities

Other Titles

Psychiatric Hospital Compare Data by Facility, Inpatient Hospital Quality Measures, CMS Quality Measures Data, IPQRF Program Quality Measures, Inpatient Psychiatric Hospital Facility Quality Measures, Inpatient Psychiatric Hospital Facility Quality Reporting Program

Data Fields

Name Description Type Constraints
State_AbbreviationTwo-letter state abbreviation in the mailing address of the hospital. This includes information on hospitals in:string-
State_HBIPS2_Measure_DescriptionDescription of State-wise Hospital Based Inpatient Psychiatric Services Core Measure Set. HBIPS2 is described as Hours of Physical Restraint Use. Total hours all patients spent in physical restraint as a proportion of total inpatient hours.string-
State_HBIPS2_Overall_Rate_Per_1000Indicates the overall rate per 1000 for HBIPS2 Measure.numberlevel : Ratio
State_HBIPS2_Overall_NumeratorIndicates the overall Numerator value for HBIPS2 Measure.numberlevel : Ratio
State_HBIPS2_Overall_DenominatorIndicates the overall Denominator value for HBIPS2 Measure.integerlevel : Ratio
State_HBIPS3_Measure_DescriptionDescription of State-wise Hospital Based Inpatient Psychiatric Services Core Measure Set. HBIPS3 is described as Hours of Seclusion Use. Total hours all patients spent in seclusion as a proportion of total inpatient hours.string-
State_HBIPS3_Overall_Rate_Per_1000Indicates the overall rate per 1000 for HBIPS3 Measure.numberlevel : Ratio
State_HBIPS3_Overall_NumeratorIndicates the overall Numerator value for HBIPS3 Measure.numberlevel : Ratio
State_HBIPS3_Overall_DenominatorIndicates the overall Denominator value for HBIPS3 Measure.integerlevel : Ratio
State_HBIPS5_Measure_DescriptionDescription of State-wise Hospital Based Inpatient Psychiatric Services Core Measure Set. HBIPS5 is described as Patients discharged on multiple antipsychotic medications with appropriate justification.Percent of patients discharged on multiple antipsychotic medications with appropriate justification as a proportion of patients discharged on two or more antipsychotic medications. Appropriate justifications are limited to augmentation of clozapine, tapering to monotherapy, and history of at least three failed trials of monotherapy.string-
State_HBIPS5_Percent_of_TotalIndicates the overall percentage for HBIPS5 Measure.numberlevel : Ratio
State_SMD_Measure_DescriptionDescription of Screening for Screening for Metabolic Disorders (SMD) Measure.string-
State_SMD_Percent_TotalIndicates the overall percentage for Screening for Metabolic Disorders (SMD) Measure.integerlevel : Ratio
State_SUB2_2a_Measure_DescriptionDescription of State-wise Substance Use Treatment Measure. It is described as Alcohol Use Brief Intervention Provided or Offered.string-
State_SUB2_PercentIndicates the overall percentage for SUB2 Measure.numberlevel : Ratio
State_SUB2a_PercentIndicates the overall percentage for SUB2a Measure.numberlevel : Ratio
State_SUB3_3a_Measure_DescriptionDescription of State-wise Substance Use Treatment Measure. SUB3 3a is described as use of Alcohol and other Drug Use Disorder Treatment Provided or Offered at Discharge.string-
State_SUB3_PercentIndicates the overall percentage for SUB3 Measure.integerlevel : Ratio
State_SUB3a_PercentIndicates the overall percentage for SUB3a Measure.integerlevel : Ratio
State_TOB2_2a_Measure_DescriptionDescription of State-wise Substance Use Treatment Measure. It is described as Tobacco Use Treatment during the hospital stay.string-
State_TOB2_PercentIndicates the overall percentage for TOB2 Measure.numberlevel : Ratio
State_TOB2a_PercentIndicates the overall percentage for TOB2a Measure.numberlevel : Ratio
State_TOB3_3a_Measure_DescriptionDescription of State-wise Substance Use Treatment Measure. It is described as Tobacco Use Treatment Provided or Offered at Discharge.string-
State_TOB3_PercentIndicates the overall percentage for TOB3 Measure.numberlevel : Ratio
State_TOB3a_PercentIndicates the overall percentage for TOB3a Measure.numberlevel : Ratio
State_TR1_Measure_DescriptionDescription of Transition record with specified elements received by discharged patients (TR1).string-
State_TR1_PercentIndicates the percentage of Transition Record with specified elements (TR1) Measure.integerlevel : Ratio
State_TR2_Measure_DescriptionDescription of Timely Transmission of transition record (TR2) Measure.string-
State_TR2_PercentIndicates the percentage of Timely Transmission of transition record (TR2) Measure.integerlevel : Ratio
Start_DateThe first day the data measures was collected. The date format is YYYY-MM-DD.date-
End_DateThe last day the data measures was collected. The date format is YYYY-MM-DD.date-
State_FUH_Measure_DescriptionDescription of Follow-Up After Hospitalization (FUH) Measure. FUH for Mental Illness measures the percentage of discharged patients age 6 years or older who had an outpatient visit, an intensive outpatient encounter, or a partial hospitalization with a mental health practitioner, within 7 days and 30 days of discharge. CMS will calculate these measures based on Medicare claims data.string-
State_FUH30_PercentIndicates the percent for Follow-up after Hospitalization (FUH) for Mental Illness of 30-Days.numberlevel : Ratio
State_FUH7_PercentIndicates the percent for Follow-up after Hospitalization (FUH) for Mental Illness of 7-Days.numberlevel : Ratio
State_FUH_Measure_Start_DateThe first day the data regarding Follow-Up After Hospitalization (FUH) Measure was collected. The date format is YYYY-MM-DD.date-
State_FUH_Measure_End_DateThe last day the data regarding Follow-Up After Hospitalization (FUH) Measure was collected. The date format is YYYY-MM-DD.date-
State_MedCont_Measure_DescriptionIt is described as Medication Continuation Following Inpatient Psychiatric Discharge.string-
State_MedCont_PercentIndicates the overall percentage for MedCon Measure.numberlevel : Ratio
State_MedCont_Measure_Start_DateThe first day the data regarding MedCont measures was collected. The date format is YYYY-MM-DD.date-
State_MedCont_Measure_End_DateThe last day the data regarding MedCont measures was collected. The date format is YYYY-MM-DD.date-
State_READM30_IPF_Measure_DescriptionDescription of Patients readmitted to any hospital within 30 days of discharge from the inpatient psychiatric facility (READM-30-IPF).string-
State_READM30_IPF_Number_IPFs_WorseIndicates the number of IPFs worse for rate of readmission after 30 days of discharge from hospital.integerlevel : Ratio
State_READM30_IPF_Number_IPFs_SameIndicates the Same number of IPFs for rate of readmission after 30 days of discharge from hospital.integerlevel : Ratio
State_READM30_IPF_Number_IPFs_BetterIndicates the number of IPFs Better for rate of readmission after 30 days of discharge from hospital.integerlevel : Ratio
State_READM30_IPF_Number_IPFs_Too_FewIndicates the number of IPFs Too Few for rate of readmission after 30 days of discharge from hospital.integerlevel : Ratio
State_READM30_IPF_Start_DateThe first day the data regarding READM30 IPF Measure was collected. The date format is YYYY-MM-DD.date-
State_READM30_IPF_End_DateThe last day the data regarding READM30 IPF Measure was collected. The date format is YYYY-MM-DD.date-
State_IMM2_Measure_DescriptionIndicates the description of State-wise Influenza Immunization Measure.string-
State_IMM2_PercentIndicates the overall percentage for IMM2 Measure.numberlevel : Ratio
Flu_Season_Start_DateThe first day the data regarding Flu Measure was collected. The date format is YYYY-MM-DD.date-
Flu_Season_End_DateThe last day the data regarding Flu Measure was collected. The date format is YYYY-MM-DD.date-
State_IPFQR_HCP_COVID19_Measure_DescriptionIt describes inpatient psychiatric hospital facility quality measures percentage of healthcare personnel who completed COVID-19 primary vaccination series (IPFQR-HCP COVID-19).string-
State_IPFQR_HCP_COVID19_PercentIndicates the overall percentage for IPFQR HCP COVID19 Measure.numberlevel : Ratio
State_IPFQR_HCP_COVID19_Start_DateThe first day the data regarding IPFQR HCP COVID19 Measure was collected. The date format is YYYY-MM-DD.date-
State_IPFQR_HCP_COVID19_End_DateThe last day the data regarding IPFQR HCP COVID19 Measure was collected. The date format is YYYY-MM-DD.date-

Data Preview

State AbbreviationState HBIPS2 Measure DescriptionState HBIPS2 Overall Rate Per 1000State HBIPS2 Overall NumeratorState HBIPS2 Overall DenominatorState HBIPS3 Measure DescriptionState HBIPS3 Overall Rate Per 1000State HBIPS3 Overall NumeratorState HBIPS3 Overall DenominatorState HBIPS5 Measure DescriptionState HBIPS5 Percent of TotalState SMD Measure DescriptionState SMD Percent TotalState SUB2 2a Measure DescriptionState SUB2 PercentState SUB2a PercentState SUB3 3a Measure DescriptionState SUB3 PercentState SUB3a PercentState TOB2 2a Measure DescriptionState TOB2 PercentState TOB2a PercentState TOB3 3a Measure DescriptionState TOB3 PercentState TOB3a PercentState TR1 Measure DescriptionState TR1 PercentStart DateEnd DateState FUH Measure DescriptionState FUH30 PercentState FUH7 PercentState FUH Measure Start DateState FUH Measure End DateState MedCont Measure DescriptionState MedCont PercentState MedCont Measure Start DateState MedCont Measure End DateState READM30 IPF Measure DescriptionState READM30 IPF Number IPFs WorseState READM30 IPF Number IPFs SameState READM30 IPF Number IPFs BetterState READM30 IPF Number IPFs Too FewState READM30 IPF Start DateState READM30 IPF End DateState IMM2 Measure DescriptionState IMM2 PercentFlu Season Start DateFlu Season End DateState IPFQR HCP COVID19 Measure DescriptionState IPFQR HCP COVID19 PercentState IPFQR HCP COVID19 Start DateState IPFQR HCP COVID19 End Date
AKHours of physical-restraint use0.18208.8547204Hours of seclusion use0.57648.2347204Patients discharged on multiple antipsychotic medications with appropriate justification86Screening for metabolic disorders (SMD)37Alcohol use brief intervention provided or offered7467Alcohol and other drug use disorder treatment provided or offered at discharge7539Tobacco use treatment provided or offered8837Tobacco use treatment provided or offered at discharge616Transition record with specified elements received by discharged patients (TR1)332022-01-012022-12-31Percent of patients receiving follow-up care within 30 days (FAPH-30) or within 7 days (FAPH-7) after psychiatric hospitalization58.736.72021-07-012022-06-30Medication Continuation Following Inpatient Psychiatric Discharge67.42020-07-012022-06-30Patients readmitted to any hospital within 30 days of discharge from the inpatient psychiatric facility (READM-30-IPF)01112020-07-012022-06-30Influenza immunization (IPFQR-IMM-2)522022-10-012023-03-31Percentage of healthcare personnel who completed COVID-19 primary vaccination series (IPFQR-HCP COVID-19)88.72023-04-012023-06-30
ALHours of physical-restraint use0.161356.32356546Hours of seclusion use0.282417.27356546Patients discharged on multiple antipsychotic medications with appropriate justification50Screening for metabolic disorders (SMD)84Alcohol use brief intervention provided or offered5581Alcohol and other drug use disorder treatment provided or offered at discharge7369Tobacco use treatment provided or offered7545Tobacco use treatment provided or offered at discharge6226Transition record with specified elements received by discharged patients (TR1)632022-01-012022-12-31Percent of patients receiving follow-up care within 30 days (FAPH-30) or within 7 days (FAPH-7) after psychiatric hospitalization52.426.52021-07-012022-06-30Medication Continuation Following Inpatient Psychiatric Discharge74.72020-07-012022-06-30Patients readmitted to any hospital within 30 days of discharge from the inpatient psychiatric facility (READM-30-IPF)235042020-07-012022-06-30Influenza immunization (IPFQR-IMM-2)852022-10-012023-03-31Percentage of healthcare personnel who completed COVID-19 primary vaccination series (IPFQR-HCP COVID-19)84.02023-04-012023-06-30
ARHours of physical-restraint use0.1726.26303411Hours of seclusion use0.282070.62303411Patients discharged on multiple antipsychotic medications with appropriate justification50Screening for metabolic disorders (SMD)84Alcohol use brief intervention provided or offered4250Alcohol and other drug use disorder treatment provided or offered at discharge6139Tobacco use treatment provided or offered8114Tobacco use treatment provided or offered at discharge669Transition record with specified elements received by discharged patients (TR1)682022-01-012022-12-31Percent of patients receiving follow-up care within 30 days (FAPH-30) or within 7 days (FAPH-7) after psychiatric hospitalization57.534.32021-07-012022-06-30Medication Continuation Following Inpatient Psychiatric Discharge79.52020-07-012022-06-30Patients readmitted to any hospital within 30 days of discharge from the inpatient psychiatric facility (READM-30-IPF)226032020-07-012022-06-30Influenza immunization (IPFQR-IMM-2)782022-10-012023-03-31Percentage of healthcare personnel who completed COVID-19 primary vaccination series (IPFQR-HCP COVID-19)89.12023-04-012023-06-30
AZHours of physical-restraint use0.365921.42689090Hours of seclusion use0.172855.43689090Patients discharged on multiple antipsychotic medications with appropriate justification40Screening for metabolic disorders (SMD)68Alcohol use brief intervention provided or offered5683Alcohol and other drug use disorder treatment provided or offered at discharge7568Tobacco use treatment provided or offered6330Tobacco use treatment provided or offered at discharge6315Transition record with specified elements received by discharged patients (TR1)532022-01-012022-12-31Percent of patients receiving follow-up care within 30 days (FAPH-30) or within 7 days (FAPH-7) after psychiatric hospitalization70.351.52021-07-012022-06-30Medication Continuation Following Inpatient Psychiatric Discharge78.02020-07-012022-06-30Patients readmitted to any hospital within 30 days of discharge from the inpatient psychiatric facility (READM-30-IPF)230122020-07-012022-06-30Influenza immunization (IPFQR-IMM-2)722022-10-012023-03-31Percentage of healthcare personnel who completed COVID-19 primary vaccination series (IPFQR-HCP COVID-19)82.42023-04-012023-06-30
CAHours of physical-restraint use0.5224678.811970239Hours of seclusion use0.3717315.01970239Patients discharged on multiple antipsychotic medications with appropriate justification53Screening for metabolic disorders (SMD)80Alcohol use brief intervention provided or offered6375Alcohol and other drug use disorder treatment provided or offered at discharge7060Tobacco use treatment provided or offered6637Tobacco use treatment provided or offered at discharge5414Transition record with specified elements received by discharged patients (TR1)612022-01-012022-12-31Percent of patients receiving follow-up care within 30 days (FAPH-30) or within 7 days (FAPH-7) after psychiatric hospitalization53.933.22021-07-012022-06-30Medication Continuation Following Inpatient Psychiatric Discharge74.02020-07-012022-06-30Patients readmitted to any hospital within 30 days of discharge from the inpatient psychiatric facility (READM-30-IPF)782132020-07-012022-06-30Influenza immunization (IPFQR-IMM-2)822022-10-012023-03-31Percentage of healthcare personnel who completed COVID-19 primary vaccination series (IPFQR-HCP COVID-19)94.92023-04-012023-06-30
COHours of physical-restraint use0.21965.61409487Hours of seclusion use0.272635.16409487Patients discharged on multiple antipsychotic medications with appropriate justification66Screening for metabolic disorders (SMD)73Alcohol use brief intervention provided or offered8584Alcohol and other drug use disorder treatment provided or offered at discharge9086Tobacco use treatment provided or offered8344Tobacco use treatment provided or offered at discharge6120Transition record with specified elements received by discharged patients (TR1)762022-01-012022-12-31Percent of patients receiving follow-up care within 30 days (FAPH-30) or within 7 days (FAPH-7) after psychiatric hospitalization64.440.42021-07-012022-06-30Medication Continuation Following Inpatient Psychiatric Discharge69.62020-07-012022-06-30Patients readmitted to any hospital within 30 days of discharge from the inpatient psychiatric facility (READM-30-IPF)015132020-07-012022-06-30Influenza immunization (IPFQR-IMM-2)852022-10-012023-03-31Percentage of healthcare personnel who completed COVID-19 primary vaccination series (IPFQR-HCP COVID-19)95.52023-04-012023-06-30
CTHours of physical-restraint use1.4612933.86368202Hours of seclusion use0.242120.73368202Patients discharged on multiple antipsychotic medications with appropriate justification57Screening for metabolic disorders (SMD)79Alcohol use brief intervention provided or offered7385Alcohol and other drug use disorder treatment provided or offered at discharge8379Tobacco use treatment provided or offered7263Tobacco use treatment provided or offered at discharge5438Transition record with specified elements received by discharged patients (TR1)342022-01-012022-12-31Percent of patients receiving follow-up care within 30 days (FAPH-30) or within 7 days (FAPH-7) after psychiatric hospitalization69.244.02021-07-012022-06-30Medication Continuation Following Inpatient Psychiatric Discharge82.42020-07-012022-06-30Patients readmitted to any hospital within 30 days of discharge from the inpatient psychiatric facility (READM-30-IPF)122112020-07-012022-06-30Influenza immunization (IPFQR-IMM-2)722022-10-012023-03-31Percentage of healthcare personnel who completed COVID-19 primary vaccination series (IPFQR-HCP COVID-19)93.82023-04-012023-06-30
DCHours of physical-restraint use0.04146.07167037Hours of seclusion use0.05207.12167037Patients discharged on multiple antipsychotic medications with appropriate justification9Screening for metabolic disorders (SMD)69Alcohol use brief intervention provided or offered4071Alcohol and other drug use disorder treatment provided or offered at discharge7657Tobacco use treatment provided or offered5431Tobacco use treatment provided or offered at discharge5514Transition record with specified elements received by discharged patients (TR1)522022-01-012022-12-31Percent of patients receiving follow-up care within 30 days (FAPH-30) or within 7 days (FAPH-7) after psychiatric hospitalization60.949.62021-07-012022-06-30Medication Continuation Following Inpatient Psychiatric Discharge62.62020-07-012022-06-30Patients readmitted to any hospital within 30 days of discharge from the inpatient psychiatric facility (READM-30-IPF)04012020-07-012022-06-30Influenza immunization (IPFQR-IMM-2)802022-10-012023-03-31Percentage of healthcare personnel who completed COVID-19 primary vaccination series (IPFQR-HCP COVID-19)98.02023-04-012023-06-30
DEHours of physical-restraint use0.11455.47167411Hours of seclusion use0.03104.87167411Patients discharged on multiple antipsychotic medications with appropriate justification70Screening for metabolic disorders (SMD)86Alcohol use brief intervention provided or offered6684Alcohol and other drug use disorder treatment provided or offered at discharge8074Tobacco use treatment provided or offered8028Tobacco use treatment provided or offered at discharge426Transition record with specified elements received by discharged patients (TR1)652022-01-012022-12-31Percent of patients receiving follow-up care within 30 days (FAPH-30) or within 7 days (FAPH-7) after psychiatric hospitalization51.227.72021-07-012022-06-30Medication Continuation Following Inpatient Psychiatric Discharge79.92020-07-012022-06-30Patients readmitted to any hospital within 30 days of discharge from the inpatient psychiatric facility (READM-30-IPF)05002020-07-012022-06-30Influenza immunization (IPFQR-IMM-2)542022-10-012023-03-31Percentage of healthcare personnel who completed COVID-19 primary vaccination series (IPFQR-HCP COVID-19)88.32023-04-012023-06-30
FLHours of physical-restraint use0.092330.811035372Hours of seclusion use0.112765.051035372Patients discharged on multiple antipsychotic medications with appropriate justification69Screening for metabolic disorders (SMD)84Alcohol use brief intervention provided or offered7780Alcohol and other drug use disorder treatment provided or offered at discharge7568Tobacco use treatment provided or offered7234Tobacco use treatment provided or offered at discharge6825Transition record with specified elements received by discharged patients (TR1)462022-01-012022-12-31Percent of patients receiving follow-up care within 30 days (FAPH-30) or within 7 days (FAPH-7) after psychiatric hospitalization55.431.82021-07-012022-06-30Medication Continuation Following Inpatient Psychiatric Discharge66.42020-07-012022-06-30Patients readmitted to any hospital within 30 days of discharge from the inpatient psychiatric facility (READM-30-IPF)2938002020-07-012022-06-30Influenza immunization (IPFQR-IMM-2)722022-10-012023-03-31Percentage of healthcare personnel who completed COVID-19 primary vaccination series (IPFQR-HCP COVID-19)81.52023-04-012023-06-30